COMPUTER ASSISTED INTERACTIVE VIDEO DONOR SCREENING

主要目标是测试适用性、可接受性和 实施和进一步开发AN的商业可行性 交互式多媒体视频献血/血浆献血者健康记录系统 操作设置。它们将通过渐进的融合来实现 将该系统纳入捐赠和数据管理过程中，并通过 逐步提高系统的复杂程度。预期收益 在以下方面有所改进： 1.血液/血浆筛查业务系统的总体性能 献血者和采集血液产品，以及 2.血液和血浆供应的安全。 将分阶段取得成果，从更新、测试开始 并安装了Talisman 1993年试验测试的独立系统。这个 Talisman多媒体系统首次获得市场许可 监管机构于1997年12月5日发布的。开发工作将按照 基于成本效益分析的SBIR一期工程建设规划 在L阶段。第一阶段的暂定终点目标是 无纸化采集系统和增强的筛查功能 系统。该计划的其他部分将涉及福利措施和 生产合规质量的成本和开发 系统。建成后，该系统将处理高达40%的血库 成本和60%的可报告错误。 建议的商业应用： 每年有超过2500万人捐献美国血液和血浆，还有三个或三个 是这个市场的四倍，这取决于有多大的潜力 实施者价值收益，该系统可能价值数千万 美元。如果该系统成功阻止了一次捐赠 这最终导致了进入血浆池的产品召回， 对制造商来说，价值可能超过100万美元。

Principal aims are to test the applicability, acceptability and commercial feasibility of implementation and further development of an interactive multimedia video blood/plasma donor health history system in operational settings. They will be achieved by progressive integration of the system into the donation and data management process and by stepwise increases in sophistication of the system. Benefits anticipated are improvement in: 1. overall performance of operational systems for screening blood/plasma donors and collecting blood products, and 2. the safety of blood and plasma supplies. Achievements will be attained in stages beginning with updating, testing and installation of Talisman's 1993 pilot tested stand-alone system. The Talisman multimedia system acquired the first ever marketing clearance from regulators on 12/5/97. Development will proceed according to the plan for SBIR Phase Il to be constructed based on cost-benefit analyses during Phase l. The tentative end point objective for Phase Il is a paperless collection system and enhanced functionality for the screening system. Other parts of the plan will address measures of benefits and costs and development of a production regulatory compliant Quality System. When completed the system will address up to 40% of blood banking costs and 60% of reportable errors. PROPOSED COMMERCIAL APPLICATIONS: With over 25,000,000 annual US blood and plasma donations, and three or four times this market world wide, depending on how potential implementers value benefits, the system could be worth tens of millions of dollars. If the system were successful in preventing just one donation that ultimately resulted in a product recall from entering a plasma pool, the value to the manufacturer could be in excess of $1,000,000.